Jayesh Desai

Recurrent SPECC1L-NTRK fusions in pediatric sarcoma and brain tumors

Dong-Anh Khuong-Quang, Lauren M Brown, Marie Wong, Chelsea Mayoh, Alexandra Sexton-Oates, Amit Kumar, Mark Pinese, Sumanth Nagabushan, Loretta Lau, Louise E Ludlow, Andrew J Gifford, Michael Rodriguez, Jayesh Desai, Stephen B Fox, Michelle Haber, David S Ziegler, Jordan R Hansford, Glenn M Marshall, Mark J Cowley, Paul G Ekert

Journal article  |  2020  |  Cold Spring Harbor molecular case studies

The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase (NTRK) family kinases in tumors h..

Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy

Hayden Snow, Catherine Mitchell, Shona Hendry, Madeleine McKinley, David Byrne, Sam Ngan, Sarat Chander, Julie Chu, Jayesh Desai, Susie Bae, Michael Henderson, Peter Choong, David Gyorki

Journal article  |  2020  |  Journal of Surgical Oncology

BACKGROUND AND OBJECTIVES: Limited literature exists examining the immune microenvironment in liposarcoma, particularly with regar..

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Wanyuan Cui, Fanny Franchini, Marliese Alexander, Ann Officer, Hui-Li Wong, Maarten IJzerman, Jayesh Desai, Benjamin J Solomon

Journal article  |  2020  |  Lung Cancer

BACKGROUND: KRAS mutations are found in 20-30 % of non-small cell lung cancers (NSCLC) and were traditionally considered undruggab..

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Jayesh Desai, Hui Gan, Catherine Barrow, Michael Jameson, Victoria Atkinson, Andrew Haydon, Michael Millward, Stephen Begbie, Michael Brown, Ben Markman, William Patterson, Andrew Hill, Lisa Horvath, Adnan Nagrial, Gary Richardson, Christopher Jackson, Michael Friedlander, Phillip Parente, Ben Tran, Lai Wang, et al.

Journal article  |  2020  |  Journal of Clinical Oncology

PURPOSE: Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This firs..

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS(G12C), in patients with advanced colorectal cancer.

Marwan Fakih, Jayesh Desai, Yasutoshi Kuboki, John H Strickler, Timothy Jay Price, Greg Andrew Durm, Gerald Steven Falchook, Crystal S Denlinger, John C Krauss, Geoffrey Shapiro, Tae Won Kim, Keunchil Park, Andrew L Coveler, Pamela N Munster, Bob T Li, June Kim, Haby Adel Henary, Gataree Ngarmchamnanrith, David S Hong

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts).

Kortnye Maureen Smith, Sophie O Haire, Anh Khuong-Quang Dong, Ben Markman, Hui Kong Gan, Paul G Ekert, Kenneth John O'Byrne, Michael Millward, Benjamin J Solomon, Ben Tran, Clare L Scott, Damien Kee, Grant A McArthur, Andrew Fellowes, Rona Weerasuriya, Elly Lynch, Melissa Martyn, Clara Gaff, Stephen B Fox, Jayesh Desai

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective

Susie Bae, Jonathan Karnon, Glenis Crane, Taryn Bessen, Jayesh Desai, Phillip Crowe, Susan Neuhaus

Journal article  |  2020  |  Cost Effectiveness and Resource Allocation

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Singh Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, Pilar Garcia-Alfonso, Ashwin Gollerkeri, Kati Maharry, Janna Christy-Bittel, Christopher Hunt Keir, Michael D Pickard, Josep Tabernero

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)

Arndt Vogel, Susanna Hegewisch-Becker, Gerald Prager, Gunnar Folprecht, Michael Stahl, Scott Kopetz, Axel Grothey, Eric van Cutsetn, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardello, Ashwin Gollerkeri, Kati Maharry, Fotios Loupakis, Y Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, et al.

Conference Proceedings  |  2020  |  ONCOLOGY RESEARCH AND TREATMENT

Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia

Rachel Delahunty, Margaret Lee, Hui-Li Wong, Julie Johns, Joseph Mckendrick, Belinda Lee, Suzanne Kosmider, Prasad Cooray, Sumitra Ananda, Jayesh Desai, Ben Tran, Jeanne Tie, Peter Gibbs, Rachel Wong

Journal article  |  2020  |  Internal Medicine Journal